Apogee Therapeutics (APGE)

• Market cap: $2.11B
• 1 day: -2.94%
• 5 days: -9.19%
• 1 month: 15.51%
• 3 months: -23.10%
• 6 months: -36.73%
• Year to date: -23.10%
• 1 year: -44.26%
• 5 years: 70.80%
• 10 years: 70.80%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Employees: 196

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

90% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 21

35% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 40

12% more funds holding

Funds holding: 139 [Q3] → 156 (+17) [Q4]

3.79% more ownership

Funds ownership: 124.72% [Q3] → 128.51% (+3.79%) [Q4]

20% less capital invested

Capital invested by funds: $3.29B [Q3] → $2.62B (-$673M) [Q4]

43% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]

49% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $3.29M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $95 162% upside
• Avg. target: $95 162% upside
• High target: $95 162% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Geoff Meacham 59% 1-year accuracy 20 / 34 met price target

162% upside $95

Buy Initiated

13 Mar 2025